Navigation Links
PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution
Date:6/21/2010

MONTEREY, Calif., June 21 /PRNewswire/ -- In a head-to-head, Phase III clinical trial of Cayston delivered by the Altera Nebulizer System versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa, the co-primary endpoint of non-inferiority for mean percent change in forced expiratory volume in one second (FEV(1)) percent predicted after 28 days of treatment was achieved.  Patients receiving Cayston had a mean increase in FEV(1) percent predicted from baseline to day 28 of 8.35 percent compared to 0.55 percent for patients receiving tobramycin inhalation solution, meeting the statistical definition of superiority for the Cayston and Altera combination.  Safety results were similar across both arms of the study, with lower incidence of cough in patients receiving Cayston.  This data was presented by Gilead Sciences during a late-breaker oral session on Friday at the 33rd European Cystic Fibrosis Conference (ECFC).  

In the study, 268 patients were randomized to receive Cayston or tobramycin inhalation solution over a 24-week treatment period.  Approximately 85 percent of patients in the study had received at least three courses of inhaled tobramycin in the 12 months prior to randomization.  Final six-month study results will become available for presentation later this year.

"We are very pleased to see these encouraging results.  Our goal is to improve therapies for respiratory care using our advanced aerosol delivery platforms, such as eFlow Technology.  In addition to aerosol delivery expertise, PARI Pharma also contributed to the initial formulation of Cayston and optimized the formulation to the Altera Nebulizer System.  As evidenced in multiple clinical trials, Altera delivers Cayston in two to three minutes – a significant reduc
'/>"/>

SOURCE PARI Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ePharmaSolutions Launches New Version of Electronic Monitor Visit Report Application With Industry-Leading Online and Offline Capabilities
2. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
3. Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
4. Pharmasset Reports Fiscal Year End 2009 Financial Results
5. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
6. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
7. Sosei Assigns AD 923 Assets to Pharmasol
8. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
9. Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
10. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
11. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... -- Today, UBM China, a wholly owned subsidiary of ... Exhibition Co., Ltd. to jointly run the Health Expo ... concurrently with CWMEE 2016. This cooperation ... MEDTEC China and DENTECH China, and fills its blank ... also another concrete cooperative project in Chengdu ...
(Date:6/30/2015)... , June 30, 2015 ... ), a clinical-stage pharmaceutical Company focused on the development ... first patient has been screened in the Company,s Phase ... U.S. based study will be performed under the active ... U.S. Food and Drug Administration (FDA). The ...
(Date:6/30/2015)...  July 4 th is this weekend, a time ... and people behind it. To help honor our current nation,s ... USA Medical Card, a leading provider of free ... empower independence for our disabled military veterans, police, firemen, and ... their prescriptions. "Due to USA ...
Breaking Medicine Technology:UBM Joins Chengdu Tianyi to Hold CWMEE 2016 2UBM Joins Chengdu Tianyi to Hold CWMEE 2016 3Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2
(Date:6/30/2015)... ... 2015 , ... iData Research ( http://www.idataresearch.com ), the leading ... policy tracking and analysis service. Reimbursement Tracker ™ enables medical device, dental, ... real-time from hundreds of insurance companies covering over 60,000 policies. , “Policy ...
(Date:6/30/2015)... Minn. (PRWEB) , ... June 30, 2015 , ... ... mobile-based nurse call and communications software, Notify™, for the senior care sector. As ... forefront of helping senior housing facilities to become more efficient and offer residents ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... D. Wagner, Chief Research and Strategy Officer at Predictive Analytics Reporting (PAR) Framework, ... National Science Foundation (NSF), will provide keynote addresses at the 2015 STEMtech conference ...
(Date:6/30/2015)... ... June 30, 2015 , ... Experts estimate that up ... life. Back pain can range from a dull, constant ache (chronic) to a sudden ... epidural steroid injections, selective nerve root blocks and rhizotomy treatment, OPTIMAL Pain ...
(Date:6/30/2015)... ... June 30, 2015 , ... Alice ... a 5-day tour in India. During her stay, she met with the ... Master Wellness™ and Transformational Leader/Internationally Beloved Spiritual Master Mahendra Trivedi to develop ...
Breaking Medicine News(10 mins):Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2Health News:Eldermark Leap-Frogs other Nurse Call and Communication Systems with Notify 2Health News:Eldermark Leap-Frogs other Nurse Call and Communication Systems with Notify 3Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 2Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 3Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 3Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 2Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 3
... have breast cancer are at increased risk of developing mood ... early online in Cancer , a peer-reviewed journal of ... address the mental health of cancer patients, loved ones. ... affected patients but of their closest relatives as well. Partners ...
... By Randy Dotinga HealthDay Reporter , FRIDAY, Sept. ... stove. You grab that hand with the other, and sometimes the ... their unusual study suggests that you can reset your brain,s image ... found that they were able to significantly decrease the levels of ...
... BOSTONIn the quest to arrest the growth and spread of ... to ignore their internal instruction manual. In a new ... created the first molecule able to prevent cancer genes from ... The study, published online by the journal Nature ...
... the growth and spread of tumors, there have been many ... manual. In a new study, a team led by ... to prevent cancer genes from "hearing" those instructions, stifling the ... by the journal Nature , demonstrates that proteins issuing ...
... cardiac care may begin almost as soon as patients ... published in Academic Emergency Medicine , Massachusetts General ... assessed for chest pain were less likely than white ... a lack of significant differences in symptoms. Such ...
... A new study looking at how hospitals account ... bloodstream infections (CA-BSIs) found substantial inconsistencies in the methods ... these infections. The study, conducted by the ... Intensive Care Unit Focus Group, appears in the October ...
Cached Medicine News:Health News:Partners of breast cancer patients are at risk of developing mood disorders 2Health News:'Self-Touch' May Reduce Pain, Study Finds 2Health News:'Self-Touch' May Reduce Pain, Study Finds 3Health News:Researchers create first molecule blocks key component of cancer genes' on-off switch 2Health News:Researchers create first molecule blocks key component of cancer genes' on-off switch 3Health News:Researchers create first molecule-blocks key component of cancer genes' on-off switch 2Health News:Researchers create first molecule-blocks key component of cancer genes' on-off switch 3Health News:Disparities in heart attack treatment may begin in the emergency room 2Health News:Disparities in heart attack treatment may begin in the emergency room 3Health News:Study of bloodstream infections reveals inconsistent surveillance methods and reporting 2
Carl Zeiss immersion oils are PCF free. They are quality controlled for two wavelengths of light, Ne=1.518 and Nd=1.515 at 23ºC....
Immersion oils may crystallize on storage. Can be redissolved on heating to 50ºC (1-2 hours)...
... Oils are the standard - the ones to ... Laboratories has consistently led in the development and ... Here is the record: , When the FDA ... of In Vitro Diagnostics in the 1970's, Cargille ...
... an Informatics software product enabling quick and ... the laboratory. With SpecTRACK Software, users can ... specimen from all laboratories in their LAN ... or cold room. Automate your existing manual ...
Medicine Products: